Business
Precigen to Present Preclinical Data for PRGN-3005 UltraCAR-T™ at the AACR Virtual Annual Meeting II in June 2020
- E-poster and audio presentation will be accessible on the AACR e-poster website on June 22, 2020 - GERMANTOWN, Md., May 15, 2020 /PRNewswire/ -- Precigen,
About this update from Precigen, Inc.
[{"type":"text","content":"- E-poster and audio presentation will be accessible on the AACR e-poster website on June 22, 2020 -\n\n\nGERMANTOWN, Md., May 15, 2020 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced preclinical data for its innovative investigational PRGN-3005 UltraCAR-T™ in patients with advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer will be presented as an e-poster at the American Association for Cancer Research (AACR) Virtual Annual Meeting II, to be held from June 22-24, 2020. The e-poster presentation titled PRGN-3005 UltraCAR-T: Multigenic CAR-T Cells Generated Using Non-viral Gene Delivery and Rapid Manufacturing Process for the Treatment of Ovarian Cancer (Abstract 6593) is part of the Immunology/Adoptive Cell Therapy session and will be accessible on the AACR e-poster website on June 22, 2020. \n\n \n \n \n \n \n \n\n \nPRGN-3005 utilizes Precigen's transformative UltraCAR‑T therapeutic platform, which eliminates ex vivo expansion and reduces manufacturing time to allow for rapid next day administration of autologous UltraCAR-T cells following non-viral gene transfer at a medical center's cGMP facility. PRGN-3005 UltraCAR-T cells simultaneously co-express a CAR specifically targeting MUC16, which is highly expressed on ovarian tumors with limited normal tissue expression; membrane bound IL-15 (mbIL15) for enhanced in vivo expansion and persistence; and a kill switch for improved therapeutic control. Ovarian cancer is the most lethal of gynecologic cancers with high unmet medical need. \n\"We are pleased to be able to share preclinical data for PRGN-3005 that led to the IND clearance and initiation of the Phase I study,\" said Helen Sabzevari, PhD, President and CEO of Precigen. \"Our preclinical results demonstrate that PRGN-3005 UltraCAR-T administered one day after non-viral gene transfer has superior anti-tumor efficacy and persistence compared to traditional CAR-T cells and represents a promising opportunity for ovarian cancer treatment. We anticipate sharing the first clinical data for PRGN-3005 in the second half of 2020.\"\nBased on these preclinical results, the FDA approved the IND application, and the first-in-human PRGN-3005 Phase I clinical trial fo...